3/2
12:36 pm
cldx
Celldex Therapeutics (CLDX) had its price target raised by The Goldman Sachs Group, Inc. from $30.00 to $34.00. They now have a "neutral" rating on the stock.
Low
Report
Celldex Therapeutics (CLDX) had its price target raised by The Goldman Sachs Group, Inc. from $30.00 to $34.00. They now have a "neutral" rating on the stock.
3/1
10:14 am
cldx
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
Low
Report
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
3/1
09:45 am
cldx
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
Low
Report
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
2/28
01:37 pm
cldx
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory [Yahoo! Finance]
2/27
09:42 pm
cldx
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential [Yahoo! Finance]
Low
Report
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential [Yahoo! Finance]
2/27
03:22 pm
cldx
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA
Low
Report
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA
2/27
02:45 pm
cldx
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA
Low
Report
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA
2/26
09:26 am
cldx
Celldex Therapeutics (CLDX) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $68.00 price target on the stock, up from $58.00.
Medium
Report
Celldex Therapeutics (CLDX) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $68.00 price target on the stock, up from $58.00.
2/25
04:50 pm
cldx
Celldex: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Celldex: Q4 Earnings Snapshot [Yahoo! Finance]
2/25
04:01 pm
cldx
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Low
Report
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
2/25
07:18 am
cldx
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria [Yahoo! Finance]
High
Report
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria [Yahoo! Finance]
2/25
07:01 am
cldx
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
High
Report
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
2/23
08:01 am
cldx
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
Medium
Report
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
2/9
08:01 am
cldx
Celldex to Present at Upcoming Investor Conferences
Medium
Report
Celldex to Present at Upcoming Investor Conferences
1/28
08:27 pm
cldx
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading Performance [Yahoo! Finance]
Low
Report
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading Performance [Yahoo! Finance]
1/13
04:15 pm
cldx
MoneyShow's Best Investment Ideas For 2026: Part 3 [Seeking Alpha]
Low
Report
MoneyShow's Best Investment Ideas For 2026: Part 3 [Seeking Alpha]
1/12
10:57 am
cldx
Celldex Therapeutics SVPs Engage In Heavy Transactions [Yahoo! Finance]
Low
Report
Celldex Therapeutics SVPs Engage In Heavy Transactions [Yahoo! Finance]
12/21
10:19 am
cldx
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 [Yahoo! Finance]
Medium
Report
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 [Yahoo! Finance]
12/21
09:01 am
cldx
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely [Yahoo! Finance]
Medium
Report
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely [Yahoo! Finance]
12/17
12:40 pm
cldx
Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.
Medium
Report
Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.
12/9
08:01 am
cldx
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
Medium
Report
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism